Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer
Abstract
Recently our laboratory identified a cytoplasmic RNA-binding protein p62 which binds to and regulates the expression of IGF II mRNA. p62 was initially shown to be recognized by auto-antibodies in hepatocellular carcinoma (HCC) but now anti-p62 has been described in diverse malignancies. p62 is uniformly expressed in fetal liver and prominently in 33% of HCC nodules, but not detectable in adult liver or normal tissue adjacent to HCC nodules. In this study, a 90 kDa protein (p90), auto-antibodies to which were found associated with anti-p62 responses in the same HCC patient group, was identified by cDNA expression cloning. Indirect immunofluorescence showed that, like p62, p90 localized to the cytoplasm in cultured cells and mouse fetal, but not adult liver. Among 11 human gastric cancer tissues examined, p90 was overexpressed in six (55%). Together with other cancer associated auto-antibodies such as anti-p53, anti-p62, anti-Koc, and anti-CENP-F, auto-antibodies to p90 represent a new marker for tumors such as HCC and gastric cancer. Our data support the working hypothesis that auto-antibody production in cancer may be directly linked to aberrant auto-antigen expression.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Full-length CIP2A is not stable enough to be purified from either E. coli or insect cells.
“full-length CIP2A is not stable enough to be purified from either E. coli or insect cells”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [31]
CIP2A is upregulated in a variety of peripheral tumors, leading to inhibition of PP2A activity.
“Cancerous Inhibitor of PP2A (CIP2A) has been shown to be upregulated in a variety of peripheral tumors, leading to an inhibition of PP2A activity (Junttila et al., 2007; Soo Hoo et al., 2002; Khanna et al., 2013a).”
From CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer’s Disease (2018) · cites this paper as Soo Hoo et al., 2002
The inhibitory effect of CIP2A on PP2A is highly specific; PP2A is the only target of CIP2A.
“First, the inhibitory effect of CIP2A on PP2A is highly specific. A large number of studies especially on cancer have shown that PP2A is the only target of CIP2A (Junttila et al., 2007; Soo Hoo et al., 2002).”
From CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer’s Disease (2018) · cites this paper as Soo Hoo et al., 2002
The citation lists haven’t been fetched yet
References 35 · Cited by 201
- Authors
- Hoo, L. S., Zhang, J. Y., & Chan, E. K.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Chan, Edward KL
- ORCID
- Chan, Edward KL
- Venue
- Oncogene
- Published
- 2002-07-16
- Volume
- 21
- Issue
- 32
- Pages
- 5006-5015
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2037657103
- Cited by
- 201
- References
- 35
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 7 · 2022: 2 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 10 · 2017: 4 · 2016: 6 · 2015: 12 · 2014: 18 · 2013: 9 · 2012: 82
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA056956, CA56956)
- National Institute of Allergy and Infectious Diseases (AI39645, R01AI039645)
- National Center for Research Resources (M01RR000833, M0-1RR00833)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- p62, P90, hepatocellular carcinoma, gastric cancer, RNA-binding proteins, tumor markers, cDNA cloning
- MeSH terms
- Adult, Amino Acid Sequence, Animals, Antigens, Neoplasm, Autoantigens, Base Sequence, Cloning, Molecular, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Molecular Sequence Data, RNA-Binding Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
